statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beam Therapeutics Begins Dosing in Phase I/II AATD Study

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment...

Beam Therapeutics (NASDAQ:BEAM) vs. Surrozen (NASDAQ:SRZN) Head-To-Head Analysis

Surrozen (NASDAQ:SRZN - Get Free Report) and Beam Therapeutics (NASDAQ:BEAM - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based...

Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $2,031,600.00 in Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 60,000 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $33.86...

2 stocks to buy in the high potential gene editing space

Investors are always on the lookout for new stocks to buy. We're looking for bargains, high-potential stocks, and dividend giants.
One area of the market that's getting a lot of attention is gene...

Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 9.2% in March

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling...

Vanguard Group Inc. Trims Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)

Vanguard Group Inc. lowered its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the Securities...

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus rating of "Hold" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings...

Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?

Beam Therapeutics (NASDAQ:BEAM) is a gene editing company one that gets less attention than its peers. Nonetheless, it currently has a $2.7 billi...

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $39.40 Consensus PT from Analysts

Beam Therapeutics Inc. (NASDAQ:BEAM  Get Free Report) has been given an average recommendation of Hold by the thirteen research firms that are covering the firm, Marketbeat.com...

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

It has been about a month since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 22.1% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Volume	1.09M
52-Wk High	$49.50
52-Wk Low	$16.95

BEAM Beam Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals